LXEO 最新10-Q变化

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial and in a Cornell investigator-initiated trial.

• In October 2025, we provided an interim clinical update, which included baseline characteristics and safety data from the 17 treated participants across the two studies, and clinical efficacy data from the 16 participants who had reached at least six months follow-up as of that time. A summary of ke…

• Improvements in LVMI among participants with abnormal baseline LVMI (n=6). Five of six participants achieved >10% by 12-month visit or sooner and six of six participants achieved LVMI measurements within the normal range as of latest visit. An 18% mean improvement in LVMI was observed at 6-month vis…

• Improvements in secondary cardiac biomarkers. Fourteen of sixteen participants achieved >25% reduction in high-sensitivity troponin I from baseline at latest visit. Fourteen of sixteen participants achieved reduction or stabilization in LWT from baseline at latest visit.

• Improvements in mFARS as demonstrated by a 2.0-point mean improvement from baseline at latest visit across all participants. Eleven of sixteen participants achieved reduction or stabilization in mFARS from baseline at latest visit.

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• Our most advanced cardiovascular product candidate, LX2006 for the treatment of FA cardiomyopathy, is currently being evaluated in SUNRISE-FA, our ongoing Phase 1/2 clinical trial, and in a Cornell investigator-initiated trial. In October 2025, we announced progress in regulatory interactions with t…

• Along with the regulatory announcement, we provided an interim clinical update on LX2006, which included baseline characteristics and safety data from the 17 treated participants across the two studies, and clinical efficacy data from the 16 participants who had reached at least six months of follow…

• Our second most advanced cardiovascular product candidate, LX2020 for the treatment of ACM caused by mutations in the PKP2 gene, referred to as PKP2-ACM, is currently being evaluated in HEROIC-PKP2, an ongoing Phase 1/2 clinical trial. We have completed enrollment and dosing in this trial, with ten …

• For the three participants in low dose cohort 1 (n=2 at 12 months; n=1 at 9 months), multiple cardiac parameters were assessed at latest visit relative to baseline:

• Arrythmia burden: Premature ventricular contractions were reduced in one of three participants and non-sustained ventricular tachycardia was reduced or stable in two of three participants.

相对上期新增的文字 · 来源:10-Q · 2026-05-11

• In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. If adverse events occur, either as a result of the product candidate or administration process, our clinical trials could be suspended or terminated. If …

• The Consolidated Appropriations Act of 2026 extended the rare pediatric disease PRV program to September 30, 2029, which means the FDA may not award any PRVs under this program after September 30, 2029, unless Congress takes further action to extend the rare pediatric disease priority review program…

• The UK government made targeted amendments to its data protection regime in the Data (Use and Access) Act 2025, which entered into force in August 2025. The European Commission renewed its adequacy determination for the UK in 2025, extending to December 2031, but the UK’s adequacy determination rema…

相对上期删除的文字 · 来源:10-Q · 2025-11-05

• In addition to side effects caused by the product candidate, the administration process or related procedures also can cause adverse side effects. Our APOE-associated Alzheimer’s disease product candidates are designed to be delivered via intracisternal administration. While the intracisternal metho…

• If adverse events occur, either as a result of the product candidate or administration process, our clinical trials could be suspended or terminated. If we cannot demonstrate that any adverse events were not caused by the drug or administration process or related procedures, the FDA, EMA or foreign …

• Under the current statutory sunset provisions, after September 30, 2024, the FDA may only award a priority review voucher, or PRV, for an approved rare pediatric disease product application if the sponsor has Rare Pediatric Disease designation for the drug or biologic that is the subject of such app…

• The UK government also introduced a Data Protection and Digital Information Bill, or the UK Bill, into the UK legislative process. The aim of the UK Bill is to reform the UK’s data protection regime following Brexit. If passed, the final version of the UK Bill may reduce the similarities between the…